# PT-141 References: The Cited Literature & FDA Label

> PT-141 (bremelanotide) references — the full cited source list: PubMed pharmacology, the RECONNECT Phase 3 trials, the fMRI study, the FDA label, and the critical re-analyses.

Every quantitative claim on this site traces to one of these sources — PubMed, the RECONNECT trials, the FDA structured product label, and the published re-analyses.

## How to read this list

These are the sources behind every cited figure on this site, in citation order. Each entry carries its authors, journal, year, and a DOI or PubMed link where one exists. Preclinical pharmacology, the pivotal Phase 3 trials, the mechanistic fMRI work, the FDA label, and the critical re-analyses are all listed so a reader can check any claim at its source. Where a study is disputed — such as the 2008 erectile-dysfunction study that received a 2023 Expression of Concern — the dispute is noted in the body text, not erased from the record.

## References

[1] Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. https://pubmed.ncbi.nlm.nih.gov/12851303/
[2] Pfaus J, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101:10201-10204. https://pubmed.ncbi.nlm.nih.gov/15226502/
[3] Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
[4] Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. https://pubmed.ncbi.nlm.nih.gov/31599847/
[5] Thurston L, Hunjan T, Mills EG, Wall MB, Ertl N, Phylactou M, et al. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. J Clin Invest. 2022;132(19):e152341. https://pubmed.ncbi.nlm.nih.gov/36189794/
[6] Borland JM, Kohut-Jackson AL, Peyla AC, Hall MA, Mermelstein PG, Meisel RL. Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. Neuropharmacology. 2025;267:110299. https://pubmed.ncbi.nlm.nih.gov/39793696/
[7] U.S. Food and Drug Administration / DailyMed. Bremelanotide Injection — US Prescribing Information. DailyMed (US FDA structured product label). 2019. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9
[8] Sweeney P, Gimenez LE, Hernandez CC, Cone RD. Targeting the central melanocortin system for the treatment of metabolic disorders. Nat Rev Endocrinol. 2023. https://pubmed.ncbi.nlm.nih.gov/37365323/
[9] Sweeney P, Gimenez LE, Hernandez CC, Cone RD. Targeting the central melanocortin system for the treatment of metabolic disorders (mechanistic review; MC4R appetite circuitry and class context). Nat Rev Endocrinol. 2023. https://doi.org/10.1038/s41574-023-00855-y
[10] Carson CC 3rd. Central nervous system-acting agents and the treatment of erectile and sexual dysfunction. Curr Urol Rep. 2007;8(6):xxx. https://pubmed.ncbi.nlm.nih.gov/18042327/
[11] Kingsberg SA, Clayton AH, Pfaus JG. The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder. CNS Drugs. 2015;29(11). https://pubmed.ncbi.nlm.nih.gov/26519340/
[12] Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. https://pubmed.ncbi.nlm.nih.gov/16412534/
[13] Kim S, Cho MC, Cho SY, Chung H, Rajasekaran MR. Novel Emerging Therapies for Erectile Dysfunction. World J Mens Health. 2021;39(1):48-64. https://pubmed.ncbi.nlm.nih.gov/32202086/
[14] Spielmans GI. Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder' in Women. J Sex Res. 2021;58(9):1085-1105. (See also Spielmans GI. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. J Sex Res. 2024.) https://pubmed.ncbi.nlm.nih.gov/33678061/

---

A two-ink lab-notebook digest of the PT-141 (bremelanotide) record — the central MC4R mechanism, the premenopausal-HSDD-only approval, and the nausea-led tolerability cost logged to source and overprinted in plain sight, with the research-chemical form kept clearly off-register from the approved drug; no clinic behind the press and nothing here dosed, dispensed, or sold.